A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
Status:
Completed
Trial end date:
2021-06-18
Target enrollment:
Participant gender:
Summary
This is a first-time-in-human (FTIH), Phase 1 study to determine the safety, tolerability,
maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) of
AZD0466 in patients with solid tumors, lymphoma and multiple myeloma at low risk for tumor
lysis syndrome (TLS), as well as in patients at intermediate risk or high risk of TLS with
hematologic malignancies for whom no standard therapy exists. Once an MTD/RP2D has been
determined in the dose escalation portion, further disease-specific expansions (solid tumor
and hematologic) will be undertaken. Combinations of AZD0466 with other standard of care
treatments may be evaluated in the future.